Pages that link to "Q34583468"
Jump to navigation
Jump to search
The following pages link to A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia (Q34583468):
Displaying 50 items.
- Drug Development Against the Major Diarrhea-Causing Parasites of the Small Intestine, Cryptosporidium and Giardia (Q26774724) (← links)
- New drug target in protozoan parasites: the role of thioredoxin reductase (Q26781548) (← links)
- Drug Resistance in the Microaerophilic Parasite Giardia lamblia (Q26800010) (← links)
- Management strategies in the treatment of neonatal and pediatric gastroenteritis (Q27004496) (← links)
- Recent advances in Entamoeba biology: RNA interference, drug discovery, and gut microbiome (Q28077685) (← links)
- Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis (Q28543559) (← links)
- Identification and Validation of Small-Gatekeeper Kinases as Drug Targets in Giardia lamblia (Q28553158) (← links)
- Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis (Q29013419) (← links)
- Hsp90 inhibitors as new leads to target parasitic diarrheal diseases (Q33798454) (← links)
- Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains (Q34070653) (← links)
- Discovery of novel antigiardiasis drug candidates (Q34597506) (← links)
- In vitro screening for drug repositioning (Q35531225) (← links)
- Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study (Q35575400) (← links)
- Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future (Q35592514) (← links)
- Metronidazole-triazole conjugates: activity against Clostridium difficile and parasites (Q35676340) (← links)
- Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections. (Q35682692) (← links)
- Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets Mia40-Erv1 Pathway (Q36266986) (← links)
- The Critical Role of the Cytoskeleton in the Pathogenesis of Giardia (Q37032497) (← links)
- Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis. (Q37037261) (← links)
- Evaluation of Giardia lamblia thioredoxin reductase as drug activating enzyme and as drug target (Q37147159) (← links)
- X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action (Q37214085) (← links)
- Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent (Q37538663) (← links)
- O(2)-dependent efficacy of novel piperidine- and piperazine-based chalcones against the human parasite Giardia intestinalis. (Q37544469) (← links)
- Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. (Q37705305) (← links)
- Proteomic and functional analyses reveal pleiotropic action of the anti-tumoral compound NBDHEX in Giardia duodenalis (Q37734423) (← links)
- Parasitic diseases in travelers: a focus on therapy (Q38192001) (← links)
- Management of chronic Giardia infection (Q38233620) (← links)
- Drug repurposing: a new front in the war against Staphylococcus aureus. (Q38834193) (← links)
- Peptide protected gold clusters: chemical synthesis and biomedical applications (Q38857692) (← links)
- Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin. (Q38916441) (← links)
- The proteasome of the differently-diverged eukaryote Giardia lamblia and its role in remodeling of the microtubule-based cytoskeleton (Q39052617) (← links)
- Treatment of giardiasis: current status and future directions (Q39257022) (← links)
- Drug susceptibility testing in microaerophilic parasites: Cysteine strongly affects the effectivities of metronidazole and auranofin, a novel and promising antimicrobial (Q40046014) (← links)
- Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo. (Q40454036) (← links)
- Auranofin: repurposing an old drug for a golden new age. (Q41474201) (← links)
- The effects of phosphanegold(I) thiolates on the biological properties of Acanthamoeba castellanii belonging to the T4 genotype (Q42121467) (← links)
- Repurposing Auranofin, Ebselen, and PX-12 as Antimicrobial Agents Targeting the Thioredoxin System (Q52647762) (← links)
- Auranofin and N-heterocyclic carbene gold-analogs are potent inhibitors of the bacteria Helicobacter pylori. (Q53781998) (← links)
- Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. (Q54289313) (← links)
- Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci. (Q55016563) (← links)
- Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum (Q56347674) (← links)
- High-Throughput Screening of Identifies Compounds Which Target Both Life Cycle Stages and Which Are Effective Against Metronidazole Resistant Parasites (Q58769320) (← links)
- Treatment-refractory giardiasis: challenges and solutions (Q59297377) (← links)
- Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings (Q64087483) (← links)
- Viability Screen of LOPAC1280 Reveals Phosphorylation Inhibitor Auranofin as a Potent Inhibitor of Blastocystis Subtype 1, 4, and 7 Isolates (Q88984609) (← links)
- Topical Therapeutic Efficacy of Ebselen Against Multidrug-Resistant Staphylococcus aureus LT-1 Targeting Thioredoxin Reductase (Q89494836) (← links)
- Drug repurposing for antimicrobial discovery (Q92128951) (← links)
- Auranofin Rapidly Eradicates Methicillin-resistant Staphylococcus aureus (MRSA) in an Infected Pressure Ulcer Mouse Model (Q94461858) (← links)
- Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection (Q94550617) (← links)
- Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak (Q99709300) (← links)